database > company
Cytori Therapeutics
Biotech Specialty Pharma
3020 Callan Road
San Diego, CA 92121 USA
phone:(858) 458-0900
fax:858-458-0994
Symbol CYTX
Exchange NASDAQ
Founded 1996
Employees 93
          www.cytoritx.com
Research Sector Biotech Specialty Pharma
Summary Description
Medical technologies to enable the practice of regenerative medicine.
Management
Christopher J. Calhoun, Chief Executive Officer; Marc H. Hedrick, M.D., President; Mark E. Saad, Chief Financial Officer; Douglas Arm, Ph.D., Vice President; Kenneth K. Kleinhenz, Vice President; Alexander M. Milstein, M.D., Vice President; Bruce Reuter, Senior Vice President; Seijiro N. Shirahama, President
Ownership
Financials Mkt Cap :248
* numbers in thousands
 
Keywords
medicine, cosmetic, reconstructive, cardiovascular, disease, wound healing


Comment | Printable Version | Modify profile Sept. 02, 2010

Description
Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products.
Products / Services
The principal products of Cytori Therapeutics include the Celution System family of products. These products processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.

The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors.

Further, it offers the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation.
Technology / Differentiation
Cytori Therapeutics goal is to provide access to clinical grade Adipose-Derived Stem and Regenerative Cells (ADRCs). ADRCs, sometimes referred to as stromal vascular fraction cells, are a heterogeneous or mixed population of cells found in adipose tissue. ADRCs are usually obtained through a simple liposuction procedure.
Market / Customers
Green Hospital Supply is responsible for all sales and marketing while Cytori is responsible for manufacturing the Celution 900/MB System and sourcing all necessary equipment.
Competitors / Substitutes / Alternatives
Aastrom Biosciences, Inc., Baxter International Inc., Osiris Therapeutics, Inc.
Status
As of December 31, 2008, the Company has two clinical trials underway in Europe for adipose-derived stem and regenerative cells, processed with the Celution 600 and 800 System, for the treatment of cardiovascular disease. Other areas for the applications of the Celution System family of products under investigation include gastrointestinal disorders, vascular disease, pelvic health conditions, and orthopedic and spinal applications.


2010-09-02-5486